Search

Your search keyword '"Cohen, Lee"' showing total 43 results
Start Over Author "Cohen, Lee" Publisher lippincott williams & wilkins
43 results on '"Cohen, Lee"'

3. Lights on MsFLASH: a review of contributions.

Author

Reed, Susan D., LaCroix, Andrea Z., Anderson, Garnet L., Ensrud, Kristine E., Caan, Bette, Carpenter, Janet S., Cohen, Lee, Diem, Susan J., Freeman, Ellen W., Joffe, Hadine, Larson, Joseph C., McCurry, Susan M., Mitchell, Caroline M., Newton, Katherine M., Sternfeld, Barbara, and Guthrie, Katherine A.

Published
2020
Full Text
View/download PDF

4. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations.

Author

Maki, Pauline M., Kornstein, Susan G., Joffe, Hadine, Bromberger, Joyce T., Freeman, Ellen W., Athappilly, Geena, Bobo, William V., Rubin, Leah H., Koleva, Hristina K., Cohen, Lee S., Soares, Claudio N., and Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers

Published
2018
Full Text
View/download PDF

23. A Putative Relationship between Valproic Acid and Polycystic Ovarian Syndrome: Implications for Treatment of Women with Seizure and Bipolar Disorders.

Author

Joffe, Hadine, Hall, Janet E., Cohen, Lee S., Taylor, Ann E., and Baldessarini, Ross J.

Subjects
BIPOLAR disorder, POLYCYSTIC ovary syndrome, VALPROIC acid
Abstract

Examines the relationship between valproic acid (VPA) and polycystic ovarian syndrome (PCOS) in women with bipolar disorder. Characteristics of patients of PCOS; Neuroendocrine abnormalities found in women with PCOS; Effect of VPA on menstrual activities and polycystic ovarian morphology.

Published
2003
Full Text
View/download PDF

26. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries1 <FN ID="FN1"><NO>1</NO>The following investigators participated in this clinical trial: Andrea Coffee, PharmD, Temple, Texas; Lee S. Cohen, MD, Boston, Massachusetts; John R. Debus, MD, Dallas, Texas; Pedro Delgado, MD, Tucson, Arizona; Joseph Fanelli, MD, Oakbrook Terrace, Illinois; Ellen W. Freeman, PhD, Philadelphia, Pennsylvania; William Gabrielli, MD, PhD, Kansas City, Kansas; Robert W. Gibson, Jr, MD, Winston-Salem, North Carolina; Uriel Halbreich, MD, Buffalo, New York; Jon F. Heiser, MD, Newport Beach, California; Donna M. Jermain, PharmD, Temple, Texas; Susan G. Kornstein, MD, Richmond, Virginia; Peter D. Londborg, MD, Seattle, Washington; Francisco Moreno, MD, Tucson, Arizona; Teri Pearlstein, MD, Providence, Rhode Island; Julian Peskin, MD, Cleveland, Ohio; Alan H. Rosenbaum, MD, Farmington Hills, Michigan; Murray Rosenthal, DO, San Diego, California; Andrea Stone, MD, Westfield, Massachusetts; and Leslie H. Taylor, MD, Middletown, Wisconsin.</FN>

Author

Cohen, Lee S., Miner, Cherri, Brown, Eileen, Freeman, Ellen W., Halbreich, Uriel, Sundell, Karen, and McCray, Susan

Subjects
*FLUOXETINE, *PREMENSTRUAL syndrome treatment, *THERAPEUTICS
Abstract

OBJECTIVE:To evaluate premenstrual daily dosing with fluoxetine for treatment of premenstrual dysphoric disorder.METHODS:After a two-cycle screening and one-cycle single-blind placebo period, 260 women were randomized to fluoxetine 10 mg, fluoxetine 20 mg, or placebo (dosed daily from 14 days before next expected menses through the first full day of bleeding) for three cycles. Women recorded premenstrual dysphoric disorder symptoms daily using a computerized version of the Daily Record of Severity of Problems.RESULTS:Premenstrual daily fluoxetine 20 mg demonstrated significant improvement in mean Daily Record of Severity of Problems luteal scores compared with placebo (P = .005); premenstrual daily fluoxetine 10 mg did not (P = .100). Daily Record of Severity of Problems total scores were statistically significantly improved by the first treatment cycle for both active treatment groups. However, only fluoxetine 20 mg remained statistically significantly superior to placebo throughout the active treatment phase of the trial. Both fluoxetine groups showed significant treatment advantage over placebo for mood-related symptoms (P < .05). Only premenstrual daily fluoxetine 20 mg showed significant treatment advantage over placebo for physical symptoms of breast tenderness (P < .001), bloating (P = .001), and joint/muscle pain (P = .037). Treatment was well tolerated; discontinuations due to adverse events did not differ among the three groups (P = .316).CONCLUSION:Premenstrual daily dosing with fluoxetine effectively treats mood, physical, and social functioning symptoms associated with premenstrual dysphoric disorder. Fluoxetine 20 mg appears to have comparable tolerability with, and better efficacy than, fluoxetine 10 mg. [Copyright &y& Elsevier]

Published
2002
Full Text
View/download PDF

42. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.

Author

Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, and Steiner M

Subjects
Adolescent, Adult, Delayed-Action Preparations, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Middle Aged, Placebos, Premenstrual Syndrome psychology, Severity of Illness Index, Treatment Outcome, Paroxetine therapeutic use, Premenstrual Syndrome drug therapy, Selective Serotonin Reuptake Inhibitors therapeutic use
Abstract

Background: Better characterization of safety and efficacy of multiple doses of selective serotonin reuptake inhibitors for the treatment of a wider range of symptoms of premenstrual dysphoric disorder (PMDD) will provide clinicians with flexibility to provide symptom relief along with acceptable tolerability. This study was designed to assess the efficacy and tolerability of multiple doses of paroxetine controlled release (CR) in PMDD., Methods: In a multicenter (43 outpatient U.S. sites), placebo-controlled trial, 327 females aged 18 to 45 years, with regular menstrual cycles, meeting DSM-IV criteria for PMDD, were randomly assigned to receive paroxetine CR 12.5 mg; paroxetine CR 25 mg; or placebo, once daily, for up to three treatment cycles. The primary efficacy outcome was change from baseline to end point in mean luteal phase Visual Analogue Scale-Mood (irritability, tension, affective lability, depressed mood) score., Results: At end point, subjects treated with paroxetine CR (12.5 mg and 25 mg) demonstrated significant improvement in VAS-Mood scores compared with those who received placebo (paroxetine CR 12.5 mg mean treatment difference vs. placebo, -8.7 mm; 95% CI, -15.7, -1.7; p =.015; paroxetine CR 25 mg mean treatment difference vs. placebo, -12.1 mm; 95% CI, -18.9, -5.3; p <.001). Results were also significant across measures of physical symptoms and social functioning. Paroxetine CR was well tolerated; 9.5% of subjects treated with 12.5 mg and 13.5% of subjects treated with 25 mg withdrew from the trial due to adverse events, compared with 6.5% of subjects in the placebo group., Conclusions: Both doses of paroxetine CR 12.5 mg and 25 mg daily are effective and well tolerated in patients who suffer from PMDD. Efficacy with both doses affords greater flexibility to the prescribing physician.

Published
2004
Full Text
View/download PDF

43. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries.

Author

Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, and McCray S

Subjects
Diagnosis, Computer-Assisted, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Fluoxetine adverse effects, Follow-Up Studies, Humans, Menstrual Cycle physiology, Mood Disorders diagnosis, Patient Compliance, Patient Satisfaction, Pregnancy, Premenstrual Syndrome prevention & control, Premenstrual Syndrome psychology, Probability, Reference Values, Selective Serotonin Reuptake Inhibitors adverse effects, Severity of Illness Index, Treatment Outcome, Fluoxetine administration & dosage, Menstrual Cycle drug effects, Mood Disorders drug therapy, Premenstrual Syndrome drug therapy, Selective Serotonin Reuptake Inhibitors administration & dosage
Abstract

Objective: To evaluate premenstrual daily dosing with fluoxetine for treatment of premenstrual dysphoric disorder., Methods: After a two-cycle screening and one-cycle single-blind placebo period, 260 women were randomized to fluoxetine 10 mg, fluoxetine 20 mg, or placebo (dosed daily from 14 days before next expected menses through the first full day of bleeding) for three cycles. Women recorded premenstrual dysphoric disorder symptoms daily using a computerized version of the Daily Record of Severity of Problems., Results: Premenstrual daily fluoxetine 20 mg demonstrated significant improvement in mean Daily Record of Severity of Problems luteal scores compared with placebo (P =.005); premenstrual daily fluoxetine 10 mg did not (P =.100). Daily Record of Severity of Problems total scores were statistically significantly improved by the first treatment cycle for both active treatment groups. However, only fluoxetine 20 mg remained statistically significantly superior to placebo throughout the active treatment phase of the trial. Both fluoxetine groups showed significant treatment advantage over placebo for mood-related symptoms (P <.05). Only premenstrual daily fluoxetine 20 mg showed significant treatment advantage over placebo for physical symptoms of breast tenderness (P <.001), bloating (P =.001), and joint/muscle pain (P =.037). Treatment was well tolerated; discontinuations due to adverse events did not differ among the three groups (P =.316)., Conclusion: Premenstrual daily dosing with fluoxetine effectively treats mood, physical, and social functioning symptoms associated with premenstrual dysphoric disorder. Fluoxetine 20 mg appears to have comparable tolerability with, and better efficacy than, fluoxetine 10 mg.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results